No registration fee. Preregistration is recommended for the in-person Orlando meeting due to limited seating. See the Location tab for hotel booking instructions.

---

  Faculty

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
Breast Cancer
Upon completion of this activity, participants should be able to

• Evaluate recently presented clinical research findings to determine their effect on the current management of localized or metastatic breast cancer.
• Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for hormone receptor (HR)-positive localized or metastatic breast cancer in order to appropriately counsel patients regarding the optimal clinical use of these agents.
• Recognize the frequency of PIK3CA/AKT1/PTEN alterations and ESR1 mutations in patients with HR-positive metastatic breast cancer (mBC), and employ evidence-based approaches designed to target these aberrations.
• Evaluate published and emerging research findings to effectively inform the selection and sequencing of available therapeutic agents and regimens for patients with HER2-positive localized and metastatic breast cancer.
• Appreciate the incidence, characteristics and clinical relevance of HER2-low or HER2-ultralow mBC, and understand available research findings with HER2-directed antibody-drug conjugates (ADCs) for patients with these diseases.
• Interrogate published and emerging Phase III research documenting the efficacy of TROP2-directed ADCs for patients with mBC to determine the current and potential clinical applicability of these approaches.
• Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for localized and metastatic breast cancer.

Prostate Cancer
Upon completion of this activity, participants should be able to

• Appraise published and emerging research findings on optimal management approaches for patients who experience biochemical recurrence after local treatment for prostate cancer, and offer appropriate counseling about the potential benefits of FDA-approved systemic treatment options.
• Evaluate the available research supporting the clinical role of oral GnRH antagonist therapy for men with advanced prostate cancer, and use this information to select optimal candidates for this strategy.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into clinical management algorithms.
• Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway in prostate cancer, and evaluate available and emerging data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
• Assess the available research database with PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
• Review available and emerging Phase III data documenting the efficacy of various forms of radioligand therapy for patients with metastatic prostate cancer, and consider the current and potential clinical role of these strategies.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.

Colorectal Cancer (CRC)
Upon completion of this activity, participants should be able to

• Understand validated biomarkers of response found in patients with CRC, such as RAS mutations, microsatellite instability (MSI)/mismatch repair (MMR) deficiency, HER2 overexpression, BRAF V600E mutations and KRAS G12C mutations, and consider the implications for molecular testing and clinical care.
• Optimize the use of neoadjuvant and adjuvant systemic therapy for patients with localized CRC, considering various clinical and biological factors, such as age, performance status, disease stage and MSI/MMR status, and the potential relevance of molecular residual disease.
• Formulate a plan to guide the selection and sequencing of therapies for individuals diagnosed with metastatic CRC (mCRC), accounting for the patient’s tumor sidedness, biomarker profile, prior systemic therapy, symptomatology and personal goals of treatment.
• Evaluate the biological rationale for immune checkpoint inhibitors in the care of patients with MSI-high/MMR-deficient localized and advanced CRC, and provide counsel regarding evidence-based and guideline-endorsed treatment recommendations.
• Appreciate published research documenting the efficacy of targeted therapeutic approaches for patients with mCRC and various actionable genomic alterations in order to personalize treatment recommendations.
• Recall ongoing trials evaluating novel agents and strategies for patients with mCRC, and use this information to refer candidates for study participation.

Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Upon completion of this activity, participants should be able to

• Identify patients with newly diagnosed and relapsed/refractory (R/R) DLBCL for whom CD79b-targeted therapy would be appropriate.
• Understand published and presented clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for DLBCL and FL, and incorporate this information into patient education discussions.
• Appraise available research findings with and current clinical role of CD19-targeted ADCs for patients with R/R DLBCL.
• Understand the biological rationale for, available research findings with and current and potential future role of Bruton tyrosine kinase inhibitors for patients with DLBCL and FL.
• Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for R/R DLBCL and FL, and counsel appropriately selected patients regarding the potential benefits of this strategy.
• Consider published research data with and current clinical role of bispecific antibodies targeting CD20 x CD3 in patients with R/R DLBCL and FL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with novel therapies commonly administered to patients with DLBCL and FL.
• Recall new data with agents and strategies currently under investigation for DLBCL and FL, and discuss ongoing trial opportunities with eligible patients.

CE Credit
CME, ABIM MOC, ABS and ACPE credit information will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 5 Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

NCPD Credit Designation Statements
This educational activity for 5 contact hours is provided by Research To Practice.
This activity is awarded 5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be remitted for ONCC/ILNA approval.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Education provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
This activity is approved for up to 0.05 CEU (5 contact hours) of continuing education credit. To receive 5 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing).

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of a CME/NCPD/ACPE-accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer (physician for CME, nurse for NCPD) for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Antonarakis — Advisory Committees: Bayer HealthCare Pharmaceuticals, DAVA Oncology, EcoR1 Capital LLC, Janssen Biotech Inc, Johnson & Johnson, Lilly, Merck, Pfizer Inc, Tango Therapeutics, Tempus, Z-Alpha; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, MacroGenics Inc, Merck, Novartis, Orion Corporation, pharmaand GmbH, Seagen Inc; Honoraria: ClearView Healthcare Partners, Curium, Lilly, Merck; Nonrelevant Financial Relationships: Fred Hutch Cancer Center, The Medical Educator Consortium. Dr Goetz — Advisory Committees (to Mayo Clinic): AstraZeneca Pharmaceuticals LP, BeOne, Biotheranostics Inc, Biotheryx, EcoR1 Capital LLC, Genentech, a member of the Roche Group, Incyclix Bio, Laekna Therapeutics, Novartis, Rna Diagnostics, Sermonix Pharmaceuticals, TerSera Therapeutics LLC; Consulting Agreements (to Mayo Clinic): Lilly, Novartis, Stemline Therapeutics; Contracted Research (to Mayo Clinic): AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Biotheryx, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Sermonix Pharmaceuticals, SimBioSys; Data and Safety Monitoring Boards/Committees (to Mayo Clinic): Pfizer Inc; Personal Fees for CME Activities: DAVA Oncology; Travel Support: Lilly; Nonrelevant Financial Relationships: AXIS Medical Education Inc, BroadcastMed, IDEOlogy Health, MJH Life Sciences, PeerView, Physician Education Resource (PER), Total Health Conferencing. Dr Lieu — Consulting Agreements (to Institution): Pfizer Inc; Contracted Research (All to Institution): Genentech, a member of the Roche Group, Janssen Biotech Inc, Sanofi. Dr Lunning — Consulting/Honoraria: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Pfizer Inc, Recordati, Regeneron Pharmaceuticals Inc, Seagen Inc, Veeva, Vittoria Biotherapeutics; Research Funding: AbbVie Inc, Bristol Myers Squibb, Fate Therapeutics, Kite, A Gilead Company. Dr McArthur — Advisory Committees: AstraZeneca Pharmaceuticals LP, ALX Oncology, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc; Contracted Research (to Institution): AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck. Dr Smith — Consulting Agreements: Foresight Diagnostics, Genmab US Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Celgene Corporation, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc. Dr Strickler — Advisory Committees: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cytovation ASA, Daiichi Sankyo Inc, GE Healthcare, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Leap Therapeutics Inc, Lilly, Merck, Natera Inc, Pfizer Inc, Pheon Therapeutics, Quanta Therapeutics, Regeneron Pharmaceuticals Inc, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Triumvira Immunologics, Xilio Therapeutics; Contracted Research: AbbVie Inc, Amgen Inc, Apollo Therapeutics, Bayer HealthCare Pharmaceuticals, BeOne, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Leap Therapeutics Inc, Lilly, Novartis, Pfizer Inc, Quanta Therapeutics, Revolution Medicines; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Johnson & Johnson; Stock Options — Private Companies: Triumvira Immunologics. Additional faculty to be announced.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

Research To Practice CME/NCPD/ACPE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

The Ritz-Carlton Orlando, Grande Lakes
4012 Central Florida Parkway
Orlando, FL 32837
Hotel Phone: (407) 206-2400

Meeting Room
Tuscany Ballroom (Salons D-H) — Lobby Level

Hotel Room Reservations

• • Florida Cancer Specialists (FCS) members, please be sure to book accommodations in the FCS room block.
• • For all other registrants, room reservation information will be included with the confirmation email after you have registered for this program.

 

Map: